imichannel

IMI Stakeholder Forum 2015

Around 1% of children are diagnosed with autism spectrum disorders (ASD), yet there are currently no drugs designed specifically to treat their main symptoms. Working to change this is the EU-AIMS project, which is supported by the Innovative Medicines Initiative (IMI). The goal of EU-AIMS is to generate tools that will enhance our understanding of ASD, and ultimately pave the way for the development of new, safe and effective treatments for use in both children and adults. As well as dramatically improving quality of life, good treatments would help to cut the social and economic costs of ASD.

The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.

IMI - www.imi.europa.eu
EU-AIMS - www.eu-aims.eu

Presentations from the IMI Stakeholder Forum 2013, which was held in Brussels on 13 May. The morning focused on IMI's brain research projects, while the afternoon featured discussions on IMI's role in the European Research Area.

Presentations from the joint IMI - C-Path event held in Brussels, Belgium on 7 March 2013.